{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:15:09Z","timestamp":1790957709103,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,12]]},"DOI":"10.7759\/cureus.77346","type":"journal-article","created":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T21:50:14Z","timestamp":1736718614000},"source":"Crossref","is-referenced-by-count":3,"title":["Effect of Ivabradine on Heart Failure: A 2024 Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Akshay","family":"Maharaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B","family":"Maturasingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Khangembam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajay N","family":"Bidhesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzey","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamille A","family":"Garness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Khadoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimish","family":"Tutwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia A","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonelle J","family":"Ramsarran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranaya","family":"Rajbhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khin Linn","family":"Htet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead N","family":"Bhagwandeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keston","family":"Rattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2020-0700","article-title":"Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction","volume":"99","author":"T\u00f3th N","year":"2021","unstructured":"T\u00f3th N, So\u00f3s A, V\u00e1radi A, et al.. Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction. Can J Physiol Pharmacol. 2021, 99:1159-74. 10.1139\/cjpp-2020-0700","journal-title":"Can J Physiol Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen A","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020, 22:1342-56. 10.1002\/ejhf.1858","journal-title":"Eur J Heart Fail"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.01.027","article-title":"Effect of ivabradine on major adverse cardiovascular events and mortality in critically ill patients: a systematic review and meta-analyses of randomised controlled trials with trial sequential analyses","volume":"124","author":"Chen A","year":"2020","unstructured":"Chen A, Elia N, Dunaiceva J, Rudiger A, Walder B, Bollen Pinto B. Effect of ivabradine on major adverse cardiovascular events and mortality in critically ill patients: a systematic review and meta-analyses of randomised controlled trials with trial sequential analyses. Br J Anaesth. 2020, 124:726-38. 10.1016\/j.bja.2020.01.027","journal-title":"Br J Anaesth"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)00252-6","article-title":"Risk stratification in hypertension: new insights from the Framingham study","volume":"1016","author":"Kannel WB","year":"2000","unstructured":"Kannel WB. Risk stratification in hypertension: new insights from the Framingham study. Am J Hypertens. 2000, 1016:0895-7061. 10.1016\/S0895-7061(99)00252-6","journal-title":"Am J Hypertens"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23581","article-title":"Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: meta-analysis of randomized controlled trials","volume":"44","author":"Bryan Richard S","year":"2021","unstructured":"Bryan Richard S, Huang B, Liu G, Yang Y, Luo S. Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: meta-analysis of randomized controlled trials. Clin Cardiol. 2021, 44:463-71. 10.1002\/clc.23581","journal-title":"Clin Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.07.725","article-title":"Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure","volume":"70","author":"Bonnet D","year":"2017","unstructured":"Bonnet D, Berger F, Jokinen E, Kantor PF, Daubeney PE. Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure. J Am Coll Cardiol. 2017, 70:1262-72. 10.1016\/j.jacc.2017.07.725","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.05.027","article-title":"Sustained-release ivabradine hemisulfate in patients with systolic\u00a0heart\u00a0failure","volume":"80","author":"Ye F","year":"2022","unstructured":"Ye F, Wang X, Wu S, et al.. Sustained-release ivabradine hemisulfate in patients with systolic\u00a0heart\u00a0failure. J Am Coll Cardiol. 2022, 80:584-94. 10.1016\/j.jacc.2022.05.027","journal-title":"J Am Coll Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-19-0227","article-title":"Efficacy and safety of ivabradine in Japanese patients with chronic heart failure\u3000- J-SHIFT Study","volume":"83","author":"Tsutsui H","year":"2019","unstructured":"Tsutsui H, Momomura SI, Yamashina A, et al.. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure\u3000- J-SHIFT Study. Circ J. 2019, 83:2049-60. 10.1253\/circj.CJ-19-0227","journal-title":"Circ J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03290-6","article-title":"Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients","volume":"78","author":"Dogheim GM","year":"2022","unstructured":"Dogheim GM, Khairat I, Omran GA, El-Haggar SM, Amrawy AM, Werida RH. Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients. Eur J Clin Pharmacol. 2022, 78:943-54. 10.1007\/s00228-022-03290-6","journal-title":"Eur J Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2017.08.009","article-title":"Heart rate manipulation in dilated cardiomyopathy: assessing the role of ivabradine","volume":"70","author":"Raja DC","year":"2018","unstructured":"Raja DC, Kapoor A, Sinha A, et al.. Heart rate manipulation in dilated cardiomyopathy: assessing the role of ivabradine. Indian Heart J. 2018, 70:246-51. 10.1016\/j.ihj.2017.08.009","journal-title":"Indian Heart J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-15-1112","article-title":"Heart rate control with if inhibitor, ivabradine, in Japanese patients with chronic heart failure\u3000- a randomized, double-blind, placebo-controlled phase II study","volume":"80","author":"Tsutsui H","year":"2016","unstructured":"Tsutsui H, Momomura S, Yamashina A, et al.. Heart rate control with if inhibitor, ivabradine, in Japanese patients with chronic heart failure\u3000- a randomized, double-blind, placebo-controlled phase II study. Circ J. 2016, 80:668-76. 10.1253\/circj.CJ-15-1112","journal-title":"Circ J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.06.043","article-title":"Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial","volume":"62","author":"Kosmala W","year":"2013","unstructured":"Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013, 62:1330-8. 10.1016\/j.jacc.2013.06.043","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1074248410370326","article-title":"Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure","volume":"15","author":"Sarullo FM","year":"2010","unstructured":"Sarullo FM, Fazio G, Puccio D, Fasullo S, Paterna S, Novo S, Di Pasquale P. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc Pharmacol Ther. 2010, 15:349-55. 10.1177\/1074248410370326","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2014.0057","article-title":"I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life","volume":"22","author":"Abdel-Salam Z","year":"2015","unstructured":"Abdel-Salam Z, Rayan M, Saleh A, Abdel-Barr MG, Hussain M, Nammas W. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life. Cardiol J. 2015, 22:227-32. 10.5603\/CJ.a2014.0057","journal-title":"Cardiol J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2011.09.001","article-title":"Efficacy of ivabradine in idiopathic dilated cardiomyopathy patients with chronic heart failure","author":"Mansour S","year":"2011","unstructured":"Mansour S, Youssef A, Rayan M, et al.. Efficacy of ivabradine in idiopathic dilated cardiomyopathy patients with chronic heart failure. Egypt Heart J. 2011, 10.1016\/j.ehj.2011.09.001","journal-title":"Egypt Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.18-559","article-title":"Ivabradine improves cardiac function and increases exercise capacity in patients with chronic heart failure","volume":"60","author":"Pei H","year":"2019","unstructured":"Pei H, Miao W, Xie WZ, Wang W, Zhao D, Su GH, Zhao Z. Ivabradine improves cardiac function and increases exercise capacity in patients with chronic heart failure. Int Heart J. 2019, 60:899-909. 10.1536\/ihj.18-559","journal-title":"Int Heart J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(79)90395-3","article-title":"Influence of heart rate on left ventricular ejection fraction in human beings","volume":"3","author":"Ricci D","year":"1979","unstructured":"Ricci D, Orlick A, Alderman E, et al.. Influence of heart rate on left ventricular ejection fraction in human beings. Am J Cardiol. 1979, 3:447-51. 10.1016\/0002-9149(79)90395-3","journal-title":"Am J Cardiol"},{"key":"ref19","article-title":"Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group","volume":"6","author":"Cintron G","year":"1993","unstructured":"Cintron G, Johnson G, Francis G, et al.. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993, 6:17-23.","journal-title":"Circulation"},{"key":"ref20","article-title":"Ivabradine (Corlanor) for heart failure: the first selective and specific IF inhibitor","volume":"40","author":"Tse S","year":"2015","unstructured":"Tse S, Mazzola N. Ivabradine (Corlanor) for heart failure: the first selective and specific IF inhibitor. P T. 2015, 40:810-4.","journal-title":"P T"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0147-3","article-title":"Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice","volume":"31","author":"Zugck C","year":"2014","unstructured":"Zugck C, Martinka P, St\u00f6ckl G. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther. 2014, 31:961-74. 10.1007\/s12325-014-0147-3","journal-title":"Adv Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-012-0467-8","article-title":"Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study","volume":"102","author":"B\u00f6hm M","year":"2013","unstructured":"B\u00f6hm M, Borer J, Ford I, et al.. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013, 102:11-22. 10.1007\/s00392-012-0467-8","journal-title":"Clin Res Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/310598-effect-of-ivabradine-on-heart-failure-a-2024-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T21:50:15Z","timestamp":1736718615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/310598-effect-of-ivabradine-on-heart-failure-a-2024-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,12]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.77346","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,12]]}}}